Trial Profile
Nolpitantium Besylate in Patients With Mild to Moderate Ulcerative Colitis, a Double-Blind, Placebo Controlled Efficacy and Safety, 8 Week Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2014
Price :
$35
*
At a glance
- Drugs Nolpitantium (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms NICE
- Sponsors Sanofi
- 14 Apr 2014 New trial record